Close Menu

NEW YORK – Becton Dickinson reported today that its fiscal year 2020 first quarter revenues rose 2 percent year over year. However, the firm lowered its guidance for the year due to evolving regulatory strategies for upgrades to its Alaris pump system.

For the three months ended Dec. 31, the company posted revenues of $4.23 billion compared to $4.16 billion in the year-ago quarter, and beat Wall Street analysts' average estimate of $4.18 billion. On a currency-neutral basis, revenues grew 2.5 percent, the firm said.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.

A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.

In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.